ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC

Core Insights - ORIC Pharmaceuticals, Inc. is set to present initial data from the Phase 1b trial of ORIC-944 in combination with androgen receptor inhibitors for metastatic castration resistant prostate cancer on May 28, 2025 [1] Company Overview - ORIC Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing treatments that address mechanisms of therapeutic resistance in cancer [4] - The company's product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) for prostate cancer, and ORIC-114, which targets specific mutations in various cancers [4] Product Details - ORIC-944 has shown potential best-in-class drug properties, including a clinical half-life of approximately 20 hours and a favorable safety profile [3] - The ongoing Phase 1b trial is evaluating ORIC-944 in combination with ERLEADA (apalutamide) and NUBEQA (darolutamide) for metastatic castration resistant prostate cancer [3]